Fig. 1: Cytokines in IMIDs and in COVID-19. | Nature Reviews Immunology

Fig. 1: Cytokines in IMIDs and in COVID-19.

From: COVID-19: risk for cytokine targeting in chronic inflammatory diseases?

Fig. 1

a | A ‘cytokine tree’ of immune-mediated inflammatory diseases (IMIDs) showing their individual responsiveness to cytokine inhibitor therapy. The risk for viral, bacterial and fungal infections and effects on blood immune cells of the respective cytokine inhibition strategies are indicated below (red equals risk and green equals no risk). b | Cytokine pathogenesis of coronavirus disease 2019 (COVID-19). AC, alveolar cell; ACE2, angiotensin-converting enzyme 2; AD, atopic dermatitis; CD, Crohn’s disease; JAK, Janus kinase; NK, natural killer; PMN, polymorphonuclear granulocyte; PsO, psoriasis; RA, rheumatoid arthritis; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SpA, spondyloarthritis; TEFF cell, T effector cell; Treg cell, regulatory T cell; UC, ulcerative colitis.

Back to article page